Incyte Corp
(NQ:
INCY
)
61.27
-0.73 (-1.18%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Incyte Corp
< Previous
1
2
3
4
5
6
Next >
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
July 30, 2024
From
Incyte
Via
Business Wire
Incyte to Report Second Quarter Financial Results
July 09, 2024
From
Incyte
Via
Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 08, 2024
From
Incyte
Via
Business Wire
Incyte Announces Final Results of Tender Offer
June 13, 2024
From
Incyte Corporation
Via
Business Wire
Incyte Announces Preliminary Results of Tender Offer
June 11, 2024
From
Incyte Corporation
Via
Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Incyte
Via
Business Wire
Incyte Completes Acquisition of Escient Pharmaceuticals
May 30, 2024
From
Incyte
Via
Business Wire
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
May 21, 2024
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conference
May 21, 2024
From
Incyte
Via
Business Wire
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
May 14, 2024
From
Incyte
Via
Business Wire
Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock
May 13, 2024
From
Incyte Corporation
Via
Business Wire
Incyte to Present at Upcoming Investor Conference
May 02, 2024
From
Incyte
Via
Business Wire
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
April 30, 2024
From
Incyte
Via
Business Wire
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
April 23, 2024
From
Incyte and Escient Pharmaceuticals
Via
Business Wire
Incyte to Report First Quarter Financial Results
April 11, 2024
From
Incyte
Via
Business Wire
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
April 01, 2024
From
Incyte
Via
Business Wire
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 29, 2024
From
Incyte
Via
Business Wire
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
March 10, 2024
From
Incyte Corporation
Via
Business Wire
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
March 10, 2024
From
Incyte
Via
Business Wire
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
March 04, 2024
From
Incyte
Via
Business Wire
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI
February 29, 2024
From
Incyte
Via
Business Wire
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
February 27, 2024
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conference
February 15, 2024
From
Incyte
Via
Business Wire
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
February 13, 2024
From
Incyte
Via
Business Wire
Pancreatic Cancer Treatments Poised for Major Advances in 2024
February 07, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
February 05, 2024
From
Incyte
Via
Business Wire
5 top healthcare stocks for earnings growth in 2024
January 25, 2024
2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed.
Via
MarketBeat
Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
January 23, 2024
From
Incyte
Via
Business Wire
Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conferences
December 12, 2023
From
Incyte
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.